Biotech with a large potential in this Week’s Analysis!

2025-09-25 Catrin Abrahamsson Uncategorized, Vikingen, Updates

Aksjeanalyser.com takes a look at an exciting biotech and pharmaceutical company!

In ‘Analysis of the Week’, Aksjeanalyser.com takes a look at a very exciting biotech and pharmaceutical company. Aksjeanalyser.com and others believe that this stock has the potential for both a 10-fold and 20-fold increase. This stock could be worth its weight in gold in the coming years.

The company Aksjeanalyser.com has looked at is: Vicore Pharma Holding

(ticker on Nasdaq Stockholm: VICO)

About the company

Vicore Pharma Holding

(Ticker on Nasdaq Stockholm: VICO)

Vicore Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for lung and cardiovascular diseases. The company researches new treatments that can improve patient outcomes and quality of life. The business is global with headquarters in Europe and North America. Vicore Pharma was founded in 2000 and is headquartered in Gothenburg, Sweden.

High potential for the Vicore share

Aksjeanalyser.com is not alone in seeing a large potential for the Vicore share, and yesterday Finansavisen.no published that Pareto sees a possible 27-fold increase for the Vicore share: Pareto: This biotech stock could make the 27-time

Analyst Dan Akschuti’s price target indicates an upside of 970 percent, but in a best-case scenario the return could be far better.

HUGE MARKET: Vicore’s drug treats a rare lung disease that is most prevalent in industrialized countries.

Source

Technical Analysis of Vicore Pharma Holding

(Ticker on Nasdaq Stockholm: VICO)

The Vicore share shows positive short term development within a rising trend. The stock has recently triggered a strong technical buy signal, after breaking upwards from an inverse head and shoulders formation.

Furthermore, the stock has had a classic consolidation to test the neckline after triggering a buy signal from this inverse head and shoulders formation. In the very short term, the stock is consolidating between SEK 10.00 and SEK 12.50.

An established break above the SEK 12.50 level would trigger new positive technical signals for the Vicore share.

The potential for the share will initially, and upon a break above the SEK 12.50 level, be up to previous peaks around SEK 30.00 – 35.00. Since 2017, the Vicore share has moved within a very large rectangle formation (see weekly chart above), and a break above the SEK 35.00 level would trigger a very strong technical buy signal for the stock.

This indicates a potential for the share right up to the SEK 165 level.

The BEST model in Vikingen is also in buy signal for Vicore Pharma Holding (VICO). This popular and effective technical analysis model was developed by Peter Östevik. He finalized the BEST model around 2019, and after 30 years of experience with technical analysis and Vikingen Financial Software.

Based on this overall very positive technical picture for Vicore Pharma Holding (VICO), Aksjeanalyser.com assesses the share as a very exciting and interesting buy candidate at the current price level around the SEK 12 level.

What could possibly change this currently positive technical picture for the Vicore share would be if the share were to fall back below the very important technical support level of around SEK 10.00 and below the 200-day moving average, which is currently around SEK 8.70.

Vicore presents at the European Respiratory Society Congress 2025

23 Sep. 08:00 ∙ MFN, source

Stockholm, September 23, 2025 — Vicore Pharma Holding AB (publ) (STO: VICO) (“Vicore”), a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), announced that the company will present at the European Respiratory Society (ERS) Congress 2025, taking place in Amsterdam, the Netherlands, from September 27 to October 1.

At the conference, Vicore will present new results from the 36-week Phase 2a AIR study of buloxibutide in idiopathic pulmonary fibrosis (IPF), including a synthetic control arm analysis. This analysis, using synthetic control arms generated from a real-world database of over 10,000 IPF patients, provides strong support for the positive treatment effect of buloxibutide. In patients with comparable baseline characteristics, buloxibutide showed a statistically significant improvement in forced vital capacity (FVC) at 36 weeks, both relative to baseline and compared to the synthetic control, confirming the disease-modifying signal observed in the AIR study.

In addition, Vicore will also share data on Almee™, a digital cognitive behavioral therapy in development, showing its impact on overall life satisfaction and quality of life in patients with pulmonary fibrosis in the US.

The background to the sharp drop in the Vicore share price on September 10, 2024

Vicore Pharma announces a rights issue of approximately SEK 782 million

Summary
– The Board of Directors of Vicore has, based on the authorization from the AGM, resolved to carry out a
new issue of shares with preferential rights for existing shareholders of approximately SEK 782 million.
– Shareholders in Vicore have preferential rights to subscribe for one (1) new share for each existing share
held, i.e. a subscription ratio of 1:1.
– The subscription price is SEK 7.00 per share in the Rights Issue.
– Upon full subscription of the Rights Issue, Vicore will receive approximately SEK 782 million before
deductions of costs related to the Rights Issue.
– The subscription period in the Rights Issue is expected to run from September 20, 2024, up to and including
October 4, 2024.
– Existing shareholdersincluding HBM Healthcare Investments, the Fourth AP Fund, Invus Public Equities LP,
HealthCap VII L.P., Unionen, SEB Investment Management and an international healthcare focused
manager, have undertaken, or expressed their intention, to subscribe for shares with and without
utilization of subscription rights corresponding to approximately 49.5 percent of the Rights Issue or
approximately SEK 387 million.

Source